Cited by 53Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsGenetic and Kidney Cyst Diseases

A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome

Du, Qiang, Wang, Yan-Jun, Yang, Sheng, Wu, Bo, Han, Ping, Zhao, Yue-Yang·2012·Current Medical Research and Opinion

Abstract

OBJECTIVE: Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS). However, the effectiveness of pioglitazone versus metformin in the treatment of PCOS remains controversial. To summarize the relative efficacy of pioglitazone and metformin in PCOS patients, a systematic review and meta-analysis of randomized controlled trials (RCTs) was performed. METHODS: The authors searched MEDLINE, EMBASE, CNKI and WANFANG DATA for articles published up to November 2011 to identify those comparing pioglitazone versus metformin as a treatment for PCOS. RESULTS: Of the 161 studies retrieved, six trials were included in this analysis, including a total of 278 women with PCOS. Pioglitazone was found to be significantly more effective than metformin at reducing fasting insulin level (P = 0.002, standardized mean differences [SMD] = -0.37, 95% confidence interval [CI] [-0.61, -0.13]). Similarly, pioglitazone was found to be significantly more effective than metformin at improving the HOMA-IR index (P = 0.014, SMD = -0.32, 95% CI [-0.57, -0.06]). However, pioglitazone was significantly less effective than metformin at reducing body mass index (BMI; P = 0.038, SMD = 0.25, 95% CI [0.01, 0.49]). The effect of pioglitazone on fasting glucose levels, testosterone levels, and Ferriman-Gallwey scores was not significantly different from that of metformin (P greater than 0.05 for all). CONCLUSION: This systematic review and meta-analysis suggests that pioglitazone was more suitable for treating hyperinsulinemia and insulin resistance among PCOS patients, while metformin was more effective in reducing body weight. Well designed RCTs are needed to provide better evidence.

Integrity signals

Registry

Crossref · 10.1185/03007995.2012.681636

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A meta-analysis including five trials comparing pioglitazone versus metformin on 258 patients showed a similar effect of the two drugs on fasting blood glucose levels, with mean difference 0.21 mmol/l (95% CI −0.46 to 0.03; p = 0.089).

    “The same group performed another meta-analysis [64] including five trials comparing pioglitazone versus metformin on 258 patients, with fasting glucose levels as an outcome. Results showed a similar effect of the two drugs on FBG levels (MD: 0.21 mmol/l; 95% CI −0.46 to 0.03; p = 0.089).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Du, Q., Wang, Y.-J., Yang, S., Wu, B., Han, P., & Zhao, Y.-Y.
Affiliations
  • Sheng Jing Hospital (CN)
  • Department of Endocrinology, Shengjing Hospital of China Medical University Liaoning ProvinceChina
  • Library, Shengjing Hospital of China Medical University Liaoning ProvinceChina
Corresponding author
Du, Qiang
Venue
Current Medical Research and Opinion
Published
2012-04-19
Volume
28
Issue
5
Pages
723-730
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2100543832
Cited by
53
References
43
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 7 · 2015: 8 · 2014: 4 · 2013: 6 · 2012: 4
FWCI
0.96
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • China Medical University
  • Shengjing Hospital
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
Keywords
polycystic ovary syndrome, pioglitazone, metformin, insulin resistance, hyperinsulinemia, HOMA-IR, fasting insulin, body mass index, hirsutism, testosterone, Ferriman-Gallwey score, fasting blood glucose
MeSH terms
Pioglitazone, Blood Glucose, Female, Hirsutism, Humans, Hyperinsulinism, Insulin Resistance, Metformin, Polycystic Ovary Syndrome, Testosterone, Body Mass Index, Randomized Controlled Trials as Topic, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review